Health Trials

Translational Immunodiagnostics in Stroke (TrImS)

ConditionsAcute Ischemic StrokeHaemorrhagic StrokeTransient Ischemic AttacksCardioembolic StrokeLarge-Artery Atherosclerosis (Embolus/Thrombosis)Small Vessel DiseaseStroke of Other Determined EtiologyStroke of Undetermined EtiologyAtrial FibrillationStroke of Anterior Cerebral ArteryStroke of Middle Cerebral ArteryStroke of Basilar Artery
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-100
SponsorThe University of Hong Kong

About this trial

In adult patients presenting to emergency departments within 24 hours of symptom onset with suspected acute stroke, we aim:

1. to identify early brain- and pathology-specific circulating, whole blood, plasma and serum panorOmic biomarkers that enable early acute stroke detection, diagnosis, dynamics, differentiation, monitoring, prediction and prognosis. 2. to identify early brain- and pathology-specific, panorOmic biomarkers in saliva that enable early acute stroke detection, diagnosis, dynamics, differentiation, monitoring, prediction and prognosis. 3. to derive biomarker platforms of models for early acute stroke detection, diagnosis, dynamics, differentiation, monitoring, prediction and prognosis 4. to validate these models in independent and external datasets

Eligibility criteria

Qualifiers

Adults ≥18 years of age.

Suspected acute stroke. Defined as either FAST-positive, or LAPSS-positive or ROSIER>0

Within 24 hours of symptom onset.

Informed consent.

Disqualifiers

Clear onset of acute symptoms >24 hours.

Trial design

Treatments tested in this trial

  • Biomarker blood draw and saliva collection

Treatment groups

650 Participants
are divided into 6 treatment groups

6

Treatment groups

See each treatment group below.

Sponsors and collaborators

The University of Hong Kong

Lead sponsor

Source ClinicalTrials.gov